➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Merck
Colorcon
Mallinckrodt
McKinsey
Baxter

Last Updated: July 10, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Refametinib


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Refametinib?

Refametinib is an investigational drug.

There have been 8 clinical trials for Refametinib. The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2013.

The most common disease conditions in clinical trials are Carcinoma, Hepatocellular, Carcinoma, and Biliary Tract Neoplasms. The leading clinical trial sponsors are Bayer, Samsung Medical Center, and [disabled in preview].

There are twenty-one US patents protecting this investigational drug and two hundred and sixty-eight international patents.

Recent Clinical Trials for Refametinib
TitleSponsorPhase
Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract AdenocarcinomaSamsung Medical CenterPhase 2
Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic CancerBayerPhase 1
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)BayerPhase 2

See all Refametinib clinical trials

Clinical Trial Summary for Refametinib

Top disease conditions for Refametinib
Top clinical trial sponsors for Refametinib

See all Refametinib clinical trials

US Patents for Refametinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Refametinib   Start Trial Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK Ardea Biosciences (San Diego, CA)   Start Trial
Refametinib   Start Trial Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,- 3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof Ardea Biosciences Inc. (San Diego, CA)   Start Trial
Refametinib   Start Trial Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK Ardea Biosciences (Costa Mesa, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Johnson and Johnson
Mallinckrodt
McKinsey
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.